Antiplatelet therapy, most notably aspirin, has been well documented to reduce risks of
subsequent cardiovascular disease (CVD) in secondary prevention, acute myocardial …

In 2007–2008, antiplatelet medications were prescribed at only 46.9% of visits for patients
with ischemic vascular disease. The evidence of the benefit of aspirin with respect to …

Aspirin therapy is well-accepted as an agent for the secondary prevention of cardiovascular
events and current guidelines also define a role for aspirin in primary prevention. In this …

Aspirin (ASA) is the most commonly prescribed antiplatelet agent. Although the evidence for
efficacy of aspirin for secondary prevention of ischemic events in patients with established …

In secondary prevention among male and female survivors of prior myocardial infarction
(MI), occlusive stroke, transient ischemic attack, and other high-risk conditions, long-term …

In secondary prevention, among a very wide range of survivors of prior occlusive
cardiovascular disease (CVD) events and those suffering acute myocardial infarction (MI) or …

Background The role of aspirin for primary prevention of cardiovascular diseases remains
controversial, particularly in the context of contemporary aggressive preventive strategies …

Aims The role of aspirin in the primary prevention setting is continuously evolving. Recent
randomized trials have challenged the role of aspirin in the primary prevention setting …

The increasing burden of cardiovascular diseases in developed, as well as developing
countries, underscores the need for the more widespread and appropriate use of aspirin in …

Aspirin has demonstrated a clear benefit in secondary prevention of coronary syndrome,
while aspirin's effect in primary prevention is unclear. This report will explore the role of …